- Home
- NSIT vs IMVT Comparison
NSIT vs IMVT Comparison
Compare NSIT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSIT
- IMVT
- Stock Information
- Founded
- NSIT 1988
- IMVT 2018
- Country
- NSIT United States
- IMVT United States
- Employees
- NSIT 14324
- IMVT N/A
- Industry
- NSIT EDP Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NSIT Technology
- IMVT Health Care
- Exchange
- NSIT Nasdaq
- IMVT Nasdaq
- Market Cap
- NSIT 2.8B
- IMVT 2.7B
- IPO Year
- NSIT 1995
- IMVT N/A
- Fundamental
- Price
- NSIT $90.13
- IMVT $22.80
- Analyst Decision
- NSIT Buy
- IMVT Buy
- Analyst Count
- NSIT 3
- IMVT 9
- Target Price
- NSIT $168.33
- IMVT $27.71
- AVG Volume (30 Days)
- NSIT 463.7K
- IMVT 2.0M
- Earning Date
- NSIT 10-30-2025
- IMVT 11-10-2025
- Dividend Yield
- NSIT N/A
- IMVT N/A
- EPS Growth
- NSIT N/A
- IMVT N/A
- EPS
- NSIT 4.21
- IMVT N/A
- Revenue
- NSIT $8,271,548,000.00
- IMVT N/A
- Revenue This Year
- NSIT N/A
- IMVT N/A
- Revenue Next Year
- NSIT $3.42
- IMVT N/A
- P/E Ratio
- NSIT $21.42
- IMVT N/A
- Revenue Growth
- NSIT N/A
- IMVT N/A
- 52 Week Low
- NSIT $89.50
- IMVT $12.72
- 52 Week High
- NSIT $181.92
- IMVT $31.65
- Technical
- Relative Strength Index (RSI)
- NSIT 15.32
- IMVT 63.89
- Support Level
- NSIT $89.50
- IMVT $21.43
- Resistance Level
- NSIT $111.54
- IMVT $23.80
- Average True Range (ATR)
- NSIT 3.26
- IMVT 1.38
- MACD
- NSIT -0.93
- IMVT -0.01
- Stochastic Oscillator
- NSIT 4.34
- IMVT 57.83
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.